Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast-like cells

Journal of Endocrinology

Volumn 192, Issue 3, 2007, Pages 639-645

  Mrak, E ^a   Villa, I ^a   Lanzi, R ^a   Losa, M ^a   Guidobono, F ^b   Rubinacci, A ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; JANUS KINASE 2; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; OSTEOPROTEGERIN; PEGVISOMANT; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BONE REMODELING; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SPACE; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANALYSIS OF VARIANCE; CELLS, CULTURED; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; OSTEOBLASTS; OSTEOPROTEGERIN; PROTEIN-TYROSINE KINASES; RECEPTORS, SOMATOTROPIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TYRPHOSTINS;

EID: 33947394915     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.07073     Document Type: Article

References (37)

1. Argetsinger LS, Campbell GS, Yang X, Witthuhn BA, Silvennoinen O, Ihle JN & Carter-Su C 1993 Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 74 237-244.
2. Barnard R, Ng KW Martin TJ & Waters MJ 1991 Growth hormone (GH) receptors in clonal osteoblast-like cells mediate a mitogenic response to GH. Endocrinology 128 1459-1464.
3. Cheung J, Mak YT, Papaioannou S, Evans BAJ, Fogelman I & Hampson G 2003 Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-β oestradiol and raloxifene. Journal of Endocrinology 177 423-433.
4. Ezzat S, Melmed S, Endres D, Eyre DR & Singer FR 1993 Biochemical assessment of bone formation and resorption in acromegaly. Journal of Clinical Endocrinology and Metabolism 76 1452-1457.
5. Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, Foged NT, Delmas PD, & Delaisse JM 1998 The collagenolytic activity of cathepsin K is unique among mammalian proteinases. Journal of Biological Chemistry 273 32347-32352.
6. Gehron Robey P & Termine JD 1985 Human bone cells in vitro. Calcified Tissue International 37 453-460.
7. Gerland K, Bataillé-Simoneau N, Baslé M, Fourcin M, Gascan H & Mercier L 2000 Activation of the Jak/Stat signal transduction pathway in GH-treated rat osteoblast-like cells in culture. Molecular and Cellular Endocrinology 168 1-9.
8. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ & Riggs BL 2000 The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. Journal of Bone and Mineral Research 15 2-12.
9. Holmes SJ, Economou G, Whitehouse RW, Adams JE & Shalet SM 1994 Reduced bone mineral density in patients with adult onset growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 78 669-674.
10. Joannsson G, Rosen T, Bosaeus I, Sjostrom L & Bengtsson BA 1996 Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult onset GH deficiency. Journal of Clinical Endocrinology and Metabolism 81 2865-2873.
11. Kanatani M, Sugimoto T, Nishiyama K & Chihara K 2000 Stimulatory effect of insulin-like growth factor binding protein-5 on mouse osteoclast formation and osteoclastic bone-resorbing activity. Journal of Bone and Mineral Research 15 902-910.
12. Kanzaki S, Baxter RC, Knutsen R, Baylink DJ & Mohan S 1995 Evidence that human bone cells in culture secrete insulin-like growth factor (IGF)-II and IGF binding protein-3 but not acid-labile subunit both under basal and regulated conditions. Journal of Bone and Mineral Research 10 854-858.
13. Kassem M, Blum W, Ristelli J, Mosekilde L & Eriksen EF 1993 Growth hormone stimulates proliferation and differentiation of normal human osteoblast-like cells in vitro. Calcified Tissue International 52 222-226.
14. Kelly PA, Ali S, Rozakis M, Goujon I, Nagano M, Pellegrini I, Gould D, Djiane J, Ederry M & Finidori J 1993 The growth hormone/prolactin receptor family. Recent Progress in Hormone Research 48 123-164.
15. Landin-Wilhelmsen K, Nilsson A, Bosaeus I & Bengtsson BA 2003 Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial. Journal of Bone and Mineral Research 18 393-405.
16. Lanzi R, Losa M, Villa I, Gatti E, Sirtori M, Dal Fiume C & Rubinacci A 2003 GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults. European Journal of Endocrinology 148 185-191.
17. Luo SM, Tan WM, Deng WX, Zhuang SM & Luo JW 2005 Expression of albumin IGFI, IGFBP3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis. World Journal of Gastroenterology 11 4272-4276.
18. Maor G, Hochberg Z, von der Mark K, Heinegard D & Silbermann M 1989 Human growth hormone enhances chondrogenesis and osteogenesis in a tissue culture system of chondroprogenitor cells. Endocrinology 125 1239-1245.
19. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S et al. 1998 Severe ostoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochemical and Biophysical Research Communication 247 610-615.
20. Nielsen HK, Jorgensen JO, Brixen K & Christiansen JS 1991 Serum osteocalcin and bone isoenzyme alkaline phosphatase in growth hormone deficient patients: dose-response studies with biosynthetic human GH. Calcified Tissue International 48 82-87.
21. Nilsson A, Swohn D, Enerback S & Ohlsson C 1995 Expression of functional growth hormone receptors in cultured human osteoblast-like cells. Journal of Clinical Endocrinology and Metabolism 80 3483-3488.
22. Nishiyama K, Sugimoto T, Kaji H, Kanatani T, Kobayashi T & Chihara K 1996 Stimulatory effect of growth hormone on bone resorption and osteoclast formation. Endocrinology 137 35-41.
23. Ohlsson C, Bengtsson BA, Isaksson OGP, Andreassen TT & Slootweg MC 1998 Growth hormone and bone. Endocrine Reviews 19 55-79.
24. Parfitt AM 1991 Growth hormone and adult bone remodelling. Clinical Endocrinology 35 467-470.
25. Rosen CJ & Wüster C 2003 Growth hormone rising: did we quit too quickly? Journal of Bone and Mineral Research 18 406-409.
26. Rubin J, Ackert-Bicknell CL, Zhu L, Fan X, Murphy TC, Nanes MS, Marcus R, Holloway L, Beamer WG & Rosen CJ 2002 IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. Journal of Clinical Endocrinology and Metabolism 87 4273-4279.
27. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF Schlenker RA, Cohn L, Rudman IW, Mattson DE et al. 1990 Effects of human growth hormone in men over 60 years old. New England Journal of Medecine 323 1562-1563.
28. Scheven BA, Hamilton NJ, Fakkeldij TM & Duursma SA 1991 Effects of recombinant human insulin-like growth factor I and II (IGF-I/-II) and growth hormone (GH) on the growth of normal adult human osteoblast-like cells and human osteogenic sarcoma cells. Growth Regulation 1 160-167.
29. Schlemmer A, Johansen JS, Pedersen SA, Jorgensen JO, Hassager C & Christiansen C 1991 The effect of growth hormone (GH) therapy on urinary pyridinoline cross-links in GH-deficient adults. Clinical Endocrinology 35 471-476.
30. Suda K, Udagawa N, Sato N, Takami M, Itoh K, Woo JT, Takahashi N & Nagai K 2004 Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation. Journal of Immunology 172 2504-2510.
31. Tashjian AH & Gagel FR, 2006 Teriparatihe [human PTH (1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. Journal of Bone and Mineral Research 21 354-365.
32. Ueland T 2004 Bone metabolism in relation to alterations in systemic growth hormone. Growth Hormone and IGF Research 14 404-417.
33. Ueland T, Bollerslev J, Flybjerg A, Hansen TB, Vahl N & Mosekilde L 2002 Effects of twelve months of GH treatment on cortical and trabecular bone of IGFs and OPG in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism 87 2760-2763.
34. Wittrant Y, Couillaud S, Theoleyre S, Dunstan C, Heymann D & Redini F 2002 Osteoprotegerin differentially regulates protease expression in osteoclast culture. Biochemical and Biaphysical Research Communication 293 38-44.
35. Wong GL, Kotliar D, Schlaeger D & Brandes SJ 1990 IGF-I production by mouse osteoblasts. Journal of Bone and Mineral Research 5 133-140.
36. Wuster C, Abs R, Bengtsson BA, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E, Monsom JP, Westberg B & Wilton P 2001 The - influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. Journal of Bone and Mineral Research 16 398-405.
37. Yamashita T, Okada S, Higashio K, Nabeshima Y & Noda M 2002 Double mutations in klotho and osteoprotegerin gene loci rescued osteopetrotic phenotype. Endocrinology 143 4711-4717.